[Prevention of respiratory syncytial virus bronchiolitis].
Marchac
Valentine
V
Hôpital Necker-Enfants malades AP-HP, Paris. v.marchac@cmsea.com
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001990:Bronchiolitis, Viral / Q000517:prevention & control*; D004311:Double-Blind Method; D005865:Gestational Age; D006266:Health Education; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D000069455:Palivizumab; D010290:Parents / Q000193:education; D016032:Randomized Controlled Trials as Topic; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage*; D018113:Respiratory Syncytial Virus, Human; D012307:Risk Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D022261:Respiratory Syncytial Virus Vaccines; D000069455:Palivizumab